Srivastava, N., Hinton, G., Krizhevsky, A., Sutskever, I
As of April 2026, Zepbound (tirzepatide) appears on the formulary with the following restrictions: Covered indications: Type 2 diabetes mellitus as an adjunct to diet and exercise Must be prescribed by a TRICARE-authorized provider Requires prior authorization regardless of plan type Subject to step therapy requirements (metformin, sulfonylureas, or other first-line agents must be tried first) Excluded indications: Obesity or weight management in patients without type 2 diabetes Overweight status (BMI 25 to 29.9) Metabolic syndrome without diagnosed diabetes Prediabetes (HbA1c 5.7% to 6.4%) Cardiovascular risk reduction in non-diabetic patients The distinction matters because Zepbound is FDA-approved for both chronic weight management (approved December 2023) and type 2 diabetes (approved May 2022 under the brand name Mounjaro)
You can add protein and all sorts of ingredients to condiments
Yes, in animal studies, Semaglutide 14mg tablets have been associated with thyroid C-cell tumors
Many operate with lean teams and rely heavily on performance marketing and affiliate channels
Patients fulfilling the above criteria who were continuously treated with an ADM for at least 1 year and had at least 1 follow-up visit at 1 of the URMC endocrine clinics were included in the final data set